**Supplementary Figure S1** In situ hybridization of U6 in normal mucosae (n = 3, upper panel) and corresponding tumor tissue (n = 3, lower panel).

**Supplementary Figure S2 (A)** MiR-188-3p is significantly up-regulated in matched cancer tissue compared to the adjacent non-cancerous mucosa (p<0.001, paired student´s t-test). **(B)** MiR-188-3p is significantly expressed at higher levels in tumors of higher tumor stage (p<0.001, ANOVA). **(C)** MiR-188-3p is significantly expressed at higher levels in tumors of microsatellite stable background.

**Supplementary Figure S3**. Kaplan-Meier curve for overall survival in the validation set of 332 colorectal cancer patients stratified according to the quartile of expression levels (p = 0.001, log-rank test).

**Supplementary Figure S4** **(A)** MiR-188-3p is expressed in all tested colorectal cancer cell lines at varying levels. **(B-D)** The WST-1 cellular growth assay shows no significant differences or trend in three different colorectal cancer cell lines transfected by control, mir-188-3p mimetic or inhibitor.

**Supplementary Figure S5** **(A-C)** No effects of miR-188-3p expression levels on drug sensitivity against commonly used colorectal cancer drugs in HCT116 cells could be observed.

**Supplementary Figure S6** **(A-C)** No effects of miR-188-3p expression levels on drug sensitivity against commonly used colorectal cancer drugs in HRT18 cells could be observed.

**Supplementary Figure S7** **(A-C)** No effects of miR-188-3p expression levels on drug sensitivity against commonly used colorectal cancer drugs in RKO cells could be observed.

**Supplementary Figure S8** **(A)** Forced expression of miR-188-3p led to a higher migration rate in HCT116 cells or **(B)** even significantly earlier and higher migration rate in RKO colorectal cancer cells (p<0.05, n=3).

**Supplementary Figure S9** **(A)** Forced expression of miR-188-3p led to early and higher rate of migration in HRT18 colorectal cancer cells (p<0.05, n = 3).

**Supplementary Figure S10 (A-B)** Transfection with a miR-188-3p inhibitor led to decreased cell migration in HCT116 cell line **(C-D),** in HRT18 cell line **(E-F)** andin the RKO cell line (p<0.05, unpaired student´s t-test, n=4)

**Supplementary Figure S11 (A)** Treatment with miR-188-3p inhibitor led to about 30% increase in MLLT4 expression after 48 hours in two independent cell lines (\*p<0.05, unpaired student´s t-test). **(B-C)** MLLT4 mRNA expression after 48 hours of MLLT4-directed siRNA transfection as measured by RT-qPCR in HCT116 and HRT18 cell line. Data are presented as mean ± SD of three independent transfection experiments in HCT116 and HRT18 cells. **(D)** MLLT4 protein expression after 48 hours of siRNA transfection as quantified by Western blot analysis in both cell lines.